Drew Ranieri
Stock Analyst at Morgan Stanley
(1.19)
# 3,714
Out of 5,044 analysts
167
Total ratings
44.44%
Success rate
-12.49%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMED Globus Medical | Maintains: Overweight | $75 → $68 | $62.75 | +8.37% | 13 | Jul 15, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $4.19 | +43.20% | 4 | Mar 5, 2025 | |
| ATEC Alphatec Holdings | Assumes: Equal-Weight | $9.5 → $10 | $16.65 | -39.94% | 10 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $375.93 | +18.37% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $15.79 | +20.33% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $15.56 | +73.52% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $6.84 | +16.96% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $25.78 | -14.66% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $10.62 | -24.67% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $14.21 | +480.58% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $20.06 | +89.43% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $50.36 | +90.63% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $11.58 | +124.53% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $184.21 | +60.14% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $130.58 | +114.43% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $6.94 | -27.95% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $22.86 | +206.21% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $545.39 | -44.99% | 6 | Apr 25, 2022 |
Globus Medical
Jul 15, 2025
Maintains: Overweight
Price Target: $75 → $68
Current: $62.75
Upside: +8.37%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $4.19
Upside: +43.20%
Alphatec Holdings
Dec 2, 2024
Assumes: Equal-Weight
Price Target: $9.5 → $10
Current: $16.65
Upside: -39.94%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $375.93
Upside: +18.37%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $15.79
Upside: +20.33%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $15.56
Upside: +73.52%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $6.84
Upside: +16.96%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $25.78
Upside: -14.66%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $10.62
Upside: -24.67%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $14.21
Upside: +480.58%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $20.06
Upside: +89.43%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $50.36
Upside: +90.63%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $11.58
Upside: +124.53%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $184.21
Upside: +60.14%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $130.58
Upside: +114.43%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $6.94
Upside: -27.95%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $22.86
Upside: +206.21%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $545.39
Upside: -44.99%